drugset / Trial / NCT05225831
Safety and Efficacy of CD19/CD22 Dual Targeted CAR-T Cell Therapy in R/R B-Cell Acute Lymphoblastic Leukemia
Phase 0
Unknown
100 enrolled
Hebei Senlang Biotechnology Inc., Ltd.
Hebei Yanda Ludaopei Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This is an open, single-arm, prospective clinical study to evaluate the safety and efficacy of anti CD19 and CD22 CAR-T cell in the treatment of R/R B-ALL.
Timeline
- Start
- 2021-08-15
- Primary completion
- 2023-08
- Completion
- 2023-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Autologous CD19/CD22 Chimeric Antigen Receptor T-cells | Cell therapy | — | — |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Fludarabine | Small molecule | — | — |